glp-1 cardiovascular outcomes 2025 news of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Comprehensive Overview of GLP-1 RAs

Resistance training does not mean you need to join a gym or lift heavy weights

As the pharmaceutical options expand and potentially become more accessible, the competitive landscape for natural GLP-1 support products will shift

This distinction was explored in a study where the Ex4-induced decline in alcohol drinking was blunted in central GLP-1R knockout mice, whereas the effect of Ex4 remained intact after peripheral GLP-1R knockout (Figure 2) ( FIGURE 2 On this note, Ex4 introduction into the NTS lowers alcohol drinking in male rats ( via NTS to regulate alcohol responses

"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet , 2023